Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

von , 18.02.2020, 13:41 Uhr

Allgemein
TORONTO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the Company’s clinical development plan for Cannabidiol (“CBD”) in the treatment of Autoimmune Hepatitis (AIH). Revive is currently

Meistgelesene Nachrichten

24h 48h 72h 7 Tage 30 Tage 3 Mo 12 Mo 24 Mo